April 20, 2018 07:56 AM EDT
Pharma

UCB snags an NDA-ready epilep­sy drug from Prox­im­a­gen in $370M deal

John Carroll

Editor & Founder

UCB is beef­ing up its pipeline of epilep­sy drugs with an NDA-ready ther­a­py from Prox­im­a­gen. The Bel­gian com­pa­ny has agreed to buy their nasal spray …

Endpoints News

Sign up to read this article for free.

Get free access to a limited number of articles, plus choose newsletters to get straight to your inbox.

BECOME A PREMIUM SUBSCRIBER
ENDPOINTS CAREERS

Global Head of Marketing

Bachem

Bubendorf, BL, Switzerland

TRENDING NOW

Pfiz­er says it has at least $10B avail­able for deals in 2025, with a fo­cus on pipeline

New study will try to stop Alzheimer’s decades be­fore it be­gins, us­ing ex­per­i­men­tal Eli Lil­ly drug

We’re about to find out which RFK Jr. will show up at HHS

Am­gen an­nounces hold on Phase 1 obe­si­ty can­di­date, pipeline cuts

Astel­las shakes up man­age­ment de­spite im­pres­sive nine-month earn­ings

Il­lu­mi­na added to Chi­na's black­list fol­low­ing Biose­cure Act, tar­iffs

A service from the Financial Times